HBV, page-7

Lawrence, what Benitec's presented late last year was not BB-103. The therapeutic construct was the same but the delivery mode was not. This means more research on safety will be required before we get to the same stage of development that we are at with BB-103. The big advantage is that the new delivery mode, in mice, reduces HBV to undetectable levels without using additional treatments. It seems the new mode is far more efficient in delivering shrna than AAV's.